Insider Selling: GSK (LON:GSK) Insider Sells 4,549 Shares of Stock

GSK plc (LON:GSK) insider Luke Miels sold 4,549 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of GBX 2,211, for a total value of £100,578.39.

GSK Trading Down 0.7%

Shares of GSK traded down GBX 15 during midday trading on Wednesday, hitting GBX 2,153. 121,524,398 shares of the stock were exchanged, compared to its average volume of 12,884,935. GSK plc has a 52-week low of GBX 1,242.50 and a 52-week high of GBX 2,219. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The stock has a fifty day simple moving average of GBX 1,861.08 and a 200 day simple moving average of GBX 1,682.05. The firm has a market cap of £86.87 billion, a P/E ratio of 16.19, a P/E/G ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last posted its quarterly earnings data on Wednesday, February 4th. The company reported GBX 172 earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. On average, research analysts anticipate that GSK plc will post 175.980975 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

GSK has been the subject of a number of research reports. Citigroup lifted their price objective on shares of GSK from GBX 1,900 to GBX 2,250 and gave the company a “buy” rating in a report on Monday. Shore Capital Group reissued a “buy” rating and issued a GBX 2,300 price target on shares of GSK in a research report on Wednesday, February 4th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of GSK from GBX 1,600 to GBX 1,675 and gave the stock a “hold” rating in a research note on Thursday, January 15th. UBS Group reiterated a “neutral” rating and issued a GBX 1,940 target price on shares of GSK in a report on Friday, January 23rd. Finally, JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of GBX 1,917.86.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.